Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Pha…
Biotechnology
US, Waltham [HQ]
Risk Factors
By Management
Not Available
No Risk Factor available yet. You can request "Risk Factors" through an email.